- Home
- TXO vs PRTA Comparison
TXO vs PRTA Comparison
Compare TXO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- PRTA
- Stock Information
- Founded
- TXO 2012
- PRTA 2012
- Country
- TXO United States
- PRTA Ireland
- Employees
- TXO N/A
- PRTA N/A
- Industry
- TXO Oil & Gas Production
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- PRTA Health Care
- Exchange
- TXO Nasdaq
- PRTA Nasdaq
- Market Cap
- TXO 699.0M
- PRTA 809.8M
- IPO Year
- TXO 2023
- PRTA N/A
- Fundamental
- Price
- TXO $17.05
- PRTA $7.43
- Analyst Decision
- TXO
- PRTA Buy
- Analyst Count
- TXO 0
- PRTA 9
- Target Price
- TXO N/A
- PRTA $51.71
- AVG Volume (30 Days)
- TXO 73.0K
- PRTA 1.4M
- Earning Date
- TXO 05-01-2025
- PRTA 05-08-2025
- Dividend Yield
- TXO 14.11%
- PRTA N/A
- EPS Growth
- TXO N/A
- PRTA N/A
- EPS
- TXO 0.40
- PRTA N/A
- Revenue
- TXO $299,696,000.00
- PRTA $137,935,000.00
- Revenue This Year
- TXO $21.35
- PRTA N/A
- Revenue Next Year
- TXO N/A
- PRTA $131.71
- P/E Ratio
- TXO $42.34
- PRTA N/A
- Revenue Growth
- TXO 3.43
- PRTA 54.55
- 52 Week Low
- TXO $15.22
- PRTA $8.00
- 52 Week High
- TXO $23.56
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- TXO 46.19
- PRTA 24.16
- Support Level
- TXO $16.86
- PRTA $9.37
- Resistance Level
- TXO $17.38
- PRTA $8.80
- Average True Range (ATR)
- TXO 0.46
- PRTA 0.67
- MACD
- TXO 0.11
- PRTA -0.09
- Stochastic Oscillator
- TXO 61.36
- PRTA 16.19
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).